• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


ORIG3N, Inc. Opens Boston, Massachusetts, Headquarters and Laboratory Campus

ORIG3N, Inc., a pioneer in the field of regenerative medicine, opened its new headquarters and laboratory in Boston, Massachusetts. The facility is located at 27 Drydock Avenue within its Innovation and Design Building in the Seaport District.

The company’s new expanded facility will provide state-of-the-art functionality to sustain collaborative research programs that support ORIG3N's cellular models called LifeSystems, as well as the company's product development and commercial activities.

ORIG3N uses iPSC technology to accelerate the future of medicine, including the pace of drug development, to overcome the trial-and-error approach common today. The firm builds and maintains the world's largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule. The new facility will help accelerate the next stage of evolution with iPSC technology, company officials said.

"Regenerative medicine is at the same stage today as the Internet was in 1993. We are on the verge of seeing huge advances in this technology and as part of our mission we are making large and diverse patient cohorts available to researchers while at the same time educating patients on what this technology is," said Robin Y. Smith, company Co-founder/CEO. "Being in Boston enables our organization to bring our technology to the epicenter of biotech research in the US."

"The foundation for the regenerative medicine revolution requires unhindered access to patient samples," Co-founder Kate Blanchard and COO said. "LifeCapsule has grown exponentially by directly engaging with consumers and patients worldwide. The remarkable growth of LifeCapsule has given ORIG3N the unique ability to create a living snapshot of humanity."

Mayor Martin J. Walsh said, "ORIG3N is a great fit for the Innovation District and our city's biotechnology and life sciences community, and we are proud to welcome them to Boston. Their work in studying rare, genetically-inherited diseases will have a huge impact on the future of medicine. ORIG3N's future is bright as they continue to expand and grow their partnerships, and we are excited that they see Boston as the best place to succeed."

Exclusive Research